Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

MEK inhibitors overcome resistance to BET inhibition across a number of solid and hematologic cancers.

Wyce A, Matteo JJ, Foley SW, Felitsky DJ, Rajapurkar SR, Zhang XP, Musso MC, Korenchuk S, Karpinich NO, Keenan KM, Stern M, Mathew LK, McHugh CF, McCabe MT, Tummino PJ, Kruger RG, Carpenter C, Barbash O.

Oncogenesis. 2018 Apr 20;7(4):35. doi: 10.1038/s41389-018-0043-9.

2.

Small-Molecule Targets in Immuno-Oncology.

Dhanak D, Edwards JP, Nguyen A, Tummino PJ.

Cell Chem Biol. 2017 Sep 21;24(9):1148-1160. doi: 10.1016/j.chembiol.2017.08.019. Review.

3.

Role of Histone-Modifying Enzymes and Their Complexes in Regulation of Chromatin Biology.

DesJarlais R, Tummino PJ.

Biochemistry. 2016 Mar 22;55(11):1584-99. doi: 10.1021/acs.biochem.5b01210. Epub 2016 Jan 26. Review.

PMID:
26745824
4.

A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC.

Mohammad HP, Smitheman KN, Kamat CD, Soong D, Federowicz KE, Van Aller GS, Schneck JL, Carson JD, Liu Y, Butticello M, Bonnette WG, Gorman SA, Degenhardt Y, Bai Y, McCabe MT, Pappalardi MB, Kasparec J, Tian X, McNulty KC, Rouse M, McDevitt P, Ho T, Crouthamel M, Hart TK, Concha NO, McHugh CF, Miller WH, Dhanak D, Tummino PJ, Carpenter CL, Johnson NW, Hann CL, Kruger RG.

Cancer Cell. 2015 Jul 13;28(1):57-69. doi: 10.1016/j.ccell.2015.06.002.

5.

A687V EZH2 is a driver of histone H3 lysine 27 (H3K27) hypertrimethylation.

Ott HM, Graves AP, Pappalardi MB, Huddleston M, Halsey WS, Hughes AM, Groy A, Dul E, Jiang Y, Bai Y, Annan R, Verma SK, Knight SD, Kruger RG, Dhanak D, Schwartz B, Tummino PJ, Creasy CL, McCabe MT.

Mol Cancer Ther. 2014 Dec;13(12):3062-73. doi: 10.1158/1535-7163.MCT-13-0876. Epub 2014 Sep 24.

6.

Control of NF-kB activity in human melanoma by bromodomain and extra-terminal protein inhibitor I-BET151.

Gallagher SJ, Mijatov B, Gunatilake D, Gowrishankar K, Tiffen J, James W, Jin L, Pupo G, Cullinane C, McArthur GA, Tummino PJ, Rizos H, Hersey P.

Pigment Cell Melanoma Res. 2014 Nov;27(6):1126-37. doi: 10.1111/pcmr.12282. Epub 2014 Jul 3.

PMID:
24924589
7.

SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer.

Mazur PK, Reynoird N, Khatri P, Jansen PW, Wilkinson AW, Liu S, Barbash O, Van Aller GS, Huddleston M, Dhanak D, Tummino PJ, Kruger RG, Garcia BA, Butte AJ, Vermeulen M, Sage J, Gozani O.

Nature. 2014 Jun 12;510(7504):283-7. doi: 10.1038/nature13320. Epub 2014 May 21.

8.

Cancer epigenetics drug discovery and development: the challenge of hitting the mark.

Campbell RM, Tummino PJ.

J Clin Invest. 2014 Jan;124(1):64-9. doi: 10.1172/JCI71605. Epub 2014 Jan 2. Review. Erratum in: J Clin Invest. 2014 Mar 3;124(3):1419.

9.

Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762.

Chaidos A, Caputo V, Gouvedenou K, Liu B, Marigo I, Chaudhry MS, Rotolo A, Tough DF, Smithers NN, Bassil AK, Chapman TD, Harker NR, Barbash O, Tummino P, Al-Mahdi N, Haynes AC, Cutler L, Le B, Rahemtulla A, Roberts I, Kleijnen M, Witherington JJ, Parr NJ, Prinjha RK, Karadimitris A.

Blood. 2014 Jan 30;123(5):697-705. doi: 10.1182/blood-2013-01-478420. Epub 2013 Dec 13.

PMID:
24335499
10.

Long residence time inhibition of EZH2 in activated polycomb repressive complex 2.

Van Aller GS, Pappalardi MB, Ott HM, Diaz E, Brandt M, Schwartz BJ, Miller WH, Dhanak D, McCabe MT, Verma SK, Creasy CL, Tummino PJ, Kruger RG.

ACS Chem Biol. 2014 Mar 21;9(3):622-9. doi: 10.1021/cb4008748. Epub 2013 Dec 31.

PMID:
24304166
11.

Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer.

Wyce A, Degenhardt Y, Bai Y, Le B, Korenchuk S, Crouthame MC, McHugh CF, Vessella R, Creasy CL, Tummino PJ, Barbash O.

Oncotarget. 2013 Dec;4(12):2419-29.

12.

BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models.

Wyce A, Ganji G, Smitheman KN, Chung CW, Korenchuk S, Bai Y, Barbash O, Le B, Craggs PD, McCabe MT, Kennedy-Wilson KM, Sanchez LV, Gosmini RL, Parr N, McHugh CF, Dhanak D, Prinjha RK, Auger KR, Tummino PJ.

PLoS One. 2013 Aug 23;8(8):e72967. doi: 10.1371/journal.pone.0072967. eCollection 2013.

13.

Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2.

Verma SK, Tian X, LaFrance LV, Duquenne C, Suarez DP, Newlander KA, Romeril SP, Burgess JL, Grant SW, Brackley JA, Graves AP, Scherzer DA, Shu A, Thompson C, Ott HM, Aller GS, Machutta CA, Diaz E, Jiang Y, Johnson NW, Knight SD, Kruger RG, McCabe MT, Dhanak D, Tummino PJ, Creasy CL, Miller WH.

ACS Med Chem Lett. 2012 Oct 19;3(12):1091-6. doi: 10.1021/ml3003346. eCollection 2012 Dec 13.

14.

EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.

McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, Liu Y, Graves AP, Della Pietra A 3rd, Diaz E, LaFrance LV, Mellinger M, Duquenne C, Tian X, Kruger RG, McHugh CF, Brandt M, Miller WH, Dhanak D, Verma SK, Tummino PJ, Creasy CL.

Nature. 2012 Dec 6;492(7427):108-12. doi: 10.1038/nature11606. Epub 2012 Oct 10.

PMID:
23051747
15.

Development and validation of reagents and assays for EZH2 peptide and nucleosome high-throughput screens.

Diaz E, Machutta CA, Chen S, Jiang Y, Nixon C, Hofmann G, Key D, Sweitzer S, Patel M, Wu Z, Creasy CL, Kruger RG, LaFrance L, Verma SK, Pappalardi MB, Le B, Van Aller GS, McCabe MT, Tummino PJ, Pope AJ, Thrall SH, Schwartz B, Brandt M.

J Biomol Screen. 2012 Dec;17(10):1279-92. doi: 10.1177/1087057112453765. Epub 2012 Aug 17.

PMID:
22904200
16.

Smyd3 regulates cancer cell phenotypes and catalyzes histone H4 lysine 5 methylation.

Van Aller GS, Reynoird N, Barbash O, Huddleston M, Liu S, Zmoos AF, McDevitt P, Sinnamon R, Le B, Mas G, Annan R, Sage J, Garcia BA, Tummino PJ, Gozani O, Kruger RG.

Epigenetics. 2012 Apr;7(4):340-3. doi: 10.4161/epi.19506. Epub 2012 Apr 1.

17.

Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27).

McCabe MT, Graves AP, Ganji G, Diaz E, Halsey WS, Jiang Y, Smitheman KN, Ott HM, Pappalardi MB, Allen KE, Chen SB, Della Pietra A 3rd, Dul E, Hughes AM, Gilbert SA, Thrall SH, Tummino PJ, Kruger RG, Brandt M, Schwartz B, Creasy CL.

Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2989-94. doi: 10.1073/pnas.1116418109. Epub 2012 Feb 8.

18.

ALDH1A1 is a novel EZH2 target gene in epithelial ovarian cancer identified by genome-wide approaches.

Li H, Bitler BG, Vathipadiekal V, Maradeo ME, Slifker M, Creasy CL, Tummino PJ, Cairns P, Birrer MJ, Zhang R.

Cancer Prev Res (Phila). 2012 Mar;5(3):484-91. doi: 10.1158/1940-6207.CAPR-11-0414. Epub 2011 Dec 5.

19.

Biochemical characterization of human HIF hydroxylases using HIF protein substrates that contain all three hydroxylation sites.

Pappalardi MB, McNulty DE, Martin JD, Fisher KE, Jiang Y, Burns MC, Zhao H, Ho T, Sweitzer S, Schwartz B, Annan RS, Copeland RA, Tummino PJ, Luo L.

Biochem J. 2011 Jun 1;436(2):363-9. doi: 10.1042/BJ20101201.

PMID:
21410436
20.

Discovery and characterization of a cell-permeable, small-molecule c-Abl kinase activator that binds to the myristoyl binding site.

Yang J, Campobasso N, Biju MP, Fisher K, Pan XQ, Cottom J, Galbraith S, Ho T, Zhang H, Hong X, Ward P, Hofmann G, Siegfried B, Zappacosta F, Washio Y, Cao P, Qu J, Bertrand S, Wang DY, Head MS, Li H, Moores S, Lai Z, Johanson K, Burton G, Erickson-Miller C, Simpson G, Tummino P, Copeland RA, Oliff A.

Chem Biol. 2011 Feb 25;18(2):177-86. doi: 10.1016/j.chembiol.2010.12.013.

21.

Epigallocatechin gallate (EGCG), a major component of green tea, is a dual phosphoinositide-3-kinase/mTOR inhibitor.

Van Aller GS, Carson JD, Tang W, Peng H, Zhao L, Copeland RA, Tummino PJ, Luo L.

Biochem Biophys Res Commun. 2011 Mar 11;406(2):194-9. doi: 10.1016/j.bbrc.2011.02.010. Epub 2011 Feb 15.

PMID:
21300025
22.

C-terminal region of USP7/HAUSP is critical for deubiquitination activity and contains a second mdm2/p53 binding site.

Ma J, Martin JD, Xue Y, Lor LA, Kennedy-Wilson KM, Sinnamon RH, Ho TF, Zhang G, Schwartz B, Tummino PJ, Lai Z.

Arch Biochem Biophys. 2010 Nov 15;503(2):207-12. doi: 10.1016/j.abb.2010.08.020. Epub 2010 Sep 15.

PMID:
20816748
23.

Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase.

Adams ND, Adams JL, Burgess JL, Chaudhari AM, Copeland RA, Donatelli CA, Drewry DH, Fisher KE, Hamajima T, Hardwicke MA, Huffman WF, Koretke-Brown KK, Lai ZV, McDonald OB, Nakamura H, Newlander KA, Oleykowski CA, Parrish CA, Patrick DR, Plant R, Sarpong MA, Sasaki K, Schmidt SJ, Silva DJ, Sutton D, Tang J, Thompson CS, Tummino PJ, Wang JC, Xiang H, Yang J, Dhanak D.

J Med Chem. 2010 May 27;53(10):3973-4001. doi: 10.1021/jm901870q.

PMID:
20420387
24.

Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin.

Knight SD, Adams ND, Burgess JL, Chaudhari AM, Darcy MG, Donatelli CA, Luengo JI, Newlander KA, Parrish CA, Ridgers LH, Sarpong MA, Schmidt SJ, Van Aller GS, Carson JD, Diamond MA, Elkins PA, Gardiner CM, Garver E, Gilbert SA, Gontarek RR, Jackson JR, Kershner KL, Luo L, Raha K, Sherk CS, Sung CM, Sutton D, Tummino PJ, Wegrzyn RJ, Auger KR, Dhanak D.

ACS Med Chem Lett. 2010 Jan 19;1(1):39-43. doi: 10.1021/ml900028r. eCollection 2010 Apr 8.

25.

Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors.

Kumar R, Crouthamel MC, Rominger DH, Gontarek RR, Tummino PJ, Levin RA, King AG.

Br J Cancer. 2009 Nov 17;101(10):1717-23. doi: 10.1038/sj.bjc.6605366. Epub 2009 Oct 20.

26.

Evidence for allosteric interactions of antagonist binding to the smoothened receptor.

Rominger CM, Bee WL, Copeland RA, Davenport EA, Gilmartin A, Gontarek R, Hornberger KR, Kallal LA, Lai Z, Lawrie K, Lu Q, McMillan L, Truong M, Tummino PJ, Turunen B, Will M, Zuercher WJ, Rominger DH.

J Pharmacol Exp Ther. 2009 Jun;329(3):995-1005. doi: 10.1124/jpet.109.152090. Epub 2009 Mar 20. Erratum in: J Pharmacol Exp Ther. 2010 Feb;332(2):690.

PMID:
19304771
27.

Biochemical characterization of GSK1070916, a potent and selective inhibitor of Aurora B and Aurora C kinases with an extremely long residence time1.

Anderson K, Lai Z, McDonald OB, Stuart JD, Nartey EN, Hardwicke MA, Newlander K, Dhanak D, Adams J, Patrick D, Copeland RA, Tummino PJ, Yang J.

Biochem J. 2009 May 13;420(2):259-65. doi: 10.1042/BJ20090121.

PMID:
19284385
28.

Biochemical characterization of human prolyl hydroxylase domain protein 2 variants associated with erythrocytosis.

Pappalardi MB, Martin JD, Jiang Y, Burns MC, Zhao H, Ho T, Sweitzer S, Lor L, Schwartz B, Duffy K, Gontarek R, Tummino PJ, Copeland RA, Luo L.

Biochemistry. 2008 Oct 28;47(43):11165-7. doi: 10.1021/bi801624f. Epub 2008 Oct 4.

PMID:
18834144
29.

Characterization of PI3K class IA isoforms with regulatory subunit p55alpha using a scintillation proximity assay.

Van Aller GS, Carson JD, Fernandes C, Lehr R, Sinnamon RH, Kirkpatrick RB, Tummino PJ, Luo L.

Anal Biochem. 2008 Dec 15;383(2):311-5. doi: 10.1016/j.ab.2008.08.037. Epub 2008 Sep 10.

PMID:
18814837
30.

Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase.

Heerding DA, Rhodes N, Leber JD, Clark TJ, Keenan RM, Lafrance LV, Li M, Safonov IG, Takata DT, Venslavsky JW, Yamashita DS, Choudhry AE, Copeland RA, Lai Z, Schaber MD, Tummino PJ, Strum SL, Wood ER, Duckett DR, Eberwein D, Knick VB, Lansing TJ, McConnell RT, Zhang S, Minthorn EA, Concha NO, Warren GL, Kumar R.

J Med Chem. 2008 Sep 25;51(18):5663-79. doi: 10.1021/jm8004527.

PMID:
18800763
31.

The catalytic role of INCENP in Aurora B activation and the kinetic mechanism of Aurora B/INCENP.

Yang J, Zappacosta F, Annan RS, Nurse K, Tummino PJ, Copeland RA, Lai Z.

Biochem J. 2009 Jan 1;417(1):355-60. doi: 10.1042/BJ20081365.

PMID:
18767990
32.

Conformation-dependent ligand regulation of ATP hydrolysis by human KSP: activation of basal hydrolysis and inhibition of microtubule-stimulated hydrolysis by a single, small molecule modulator.

Luo L, Carson JD, Molnar KS, Tuske SJ, Coales SJ, Hamuro Y, Sung CM, Sudakin V, Auger KR, Dhanak D, Jackson JR, Huang PS, Tummino PJ, Copeland RA.

J Am Chem Soc. 2008 Jun 18;130(24):7584-91. doi: 10.1021/ja710889h. Epub 2008 May 21.

PMID:
18491908
33.

Residence time of receptor-ligand complexes and its effect on biological function.

Tummino PJ, Copeland RA.

Biochemistry. 2008 May 20;47(20):5481-92. doi: 10.1021/bi8002023. Epub 2008 Apr 16. Review. Erratum in: Biochemistry. 2008 Aug 12;47(32):8465.

PMID:
18412369
34.

Characterization of an exosite binding inhibitor of matrix metalloproteinase 13.

Gooljarsingh LT, Lakdawala A, Coppo F, Luo L, Fields GB, Tummino PJ, Gontarek RR.

Protein Sci. 2008 Jan;17(1):66-71. Epub 2007 Nov 27.

35.

Effects of oncogenic p110alpha subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase.

Carson JD, Van Aller G, Lehr R, Sinnamon RH, Kirkpatrick RB, Auger KR, Dhanak D, Copeland RA, Gontarek RR, Tummino PJ, Luo L.

Biochem J. 2008 Jan 15;409(2):519-24.

PMID:
17877460
36.

Binding of TPX2 to Aurora A alters substrate and inhibitor interactions.

Anderson K, Yang J, Koretke K, Nurse K, Calamari A, Kirkpatrick RB, Patrick D, Silva D, Tummino PJ, Copeland RA, Lai Z.

Biochemistry. 2007 Sep 11;46(36):10287-95. Epub 2007 Aug 18.

PMID:
17705509
37.

Targeting enzyme inhibitors in drug discovery.

Copeland RA, Harpel MR, Tummino PJ.

Expert Opin Ther Targets. 2007 Jul;11(7):967-78.

PMID:
17614764
38.

A second p53 binding site in the central domain of Mdm2 is essential for p53 ubiquitination.

Ma J, Martin JD, Zhang H, Auger KR, Ho TF, Kirkpatrick RB, Grooms MH, Johanson KO, Tummino PJ, Copeland RA, Lai Z.

Biochemistry. 2006 Aug 1;45(30):9238-45.

PMID:
16866370
39.

A biochemical rationale for the anticancer effects of Hsp90 inhibitors: slow, tight binding inhibition by geldanamycin and its analogues.

Gooljarsingh LT, Fernandes C, Yan K, Zhang H, Grooms M, Johanson K, Sinnamon RH, Kirkpatrick RB, Kerrigan J, Lewis T, Arnone M, King AJ, Lai Z, Copeland RA, Tummino PJ.

Proc Natl Acad Sci U S A. 2006 May 16;103(20):7625-30. Epub 2006 May 9.

40.

Identification and characterization of 4-aryl-3,4-dihydropyrimidin-2(1H)-ones as inhibitors of the fatty acid transporter FATP4.

Blackburn C, Guan B, Brown J, Cullis C, Condon SM, Jenkins TJ, Peluso S, Ye Y, Gimeno RE, Punreddy S, Sun Y, Wu H, Hubbard B, Kaushik V, Tummino P, Sanchetti P, Yu Sun D, Daniels T, Tozzo E, Balani SK, Raman P.

Bioorg Med Chem Lett. 2006 Jul 1;16(13):3504-9. Epub 2006 Apr 27.

PMID:
16644217
41.

An assay for Fe(II)/2-oxoglutarate-dependent dioxygenases by enzyme-coupled detection of succinate formation.

Luo L, Pappalardi MB, Tummino PJ, Copeland RA, Fraser ME, Grzyska PK, Hausinger RP.

Anal Biochem. 2006 Jun 1;353(1):69-74. Epub 2006 Apr 19.

PMID:
16643838
42.

Expression, purification, and enzymatic characterization of the dual specificity mitogen-activated protein kinase phosphatase, MKP-4.

Hong SB, Lubben TH, Dolliver CM, Petrolonis AJ, Roy RA, Li Z, Parsons TF, Li P, Xu H, Reilly RM, Trevillyan JM, Nichols AJ, Tummino PJ, Gant TG.

Bioorg Chem. 2005 Feb;33(1):34-44.

PMID:
15668181
43.

Enzymatic characterization of the pancreatic islet-specific glucose-6-phosphatase-related protein (IGRP).

Petrolonis AJ, Yang Q, Tummino PJ, Fish SM, Prack AE, Jain S, Parsons TF, Li P, Dales NA, Ge L, Langston SP, Schuller AG, An WF, Tartaglia LA, Chen H, Hong SB.

J Biol Chem. 2004 Apr 2;279(14):13976-83. Epub 2004 Jan 13.

44.

Substrate-based design of the first class of angiotensin-converting enzyme-related carboxypeptidase (ACE2) inhibitors.

Dales NA, Gould AE, Brown JA, Calderwood EF, Guan B, Minor CA, Gavin JM, Hales P, Kaushik VK, Stewart M, Tummino PJ, Vickers CS, Ocain TD, Patane MA.

J Am Chem Soc. 2002 Oct 9;124(40):11852-3.

PMID:
12358520
45.

Helicobacter pylori 3-deoxy-D-manno-octulosonate-8-phosphate (KDO-8-P) synthase is a zinc-metalloenzyme.

Krosky DJ, Alm R, Berg M, Carmel G, Tummino PJ, Xu B, Yang W.

Biochim Biophys Acta. 2002 Feb 11;1594(2):297-306.

PMID:
11904225
46.

Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase.

Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, Godbout K, Parsons T, Baronas E, Hsieh F, Acton S, Patane M, Nichols A, Tummino P.

J Biol Chem. 2002 Apr 26;277(17):14838-43. Epub 2002 Jan 28.

47.

5,6-Dihydropyran-2-ones possessing various sulfonyl functionalities: potent nonpeptidic inhibitors of HIV protease.

Boyer FE, Vara Prasad JV, Domagala JM, Ellsworth EL, Gajda C, Hagen SE, Markoski LJ, Tait BD, Lunney EA, Palovsky A, Ferguson D, Graham N, Holler T, Hupe D, Nouhan C, Tummino PJ, Urumov A, Zeikus E, Zeikus G, Gracheck SJ, Sanders JM, VanderRoest S, Brodfuehrer J, Iyer K, Sinz M, Gulnik SV.

J Med Chem. 2000 Mar 9;43(5):843-58.

PMID:
10715152
48.

Nonpeptidic HIV protease inhibitors possessing excellent antiviral activities and therapeutic indices. PD 178390: a lead HIV protease inhibitor.

Prasad JV, Boyer FE, Domagala JM, Ellsworth EL, Gajda C, Hamilton HW, Hagen SE, Markoski LJ, Steinbaugh BA, Tait BD, Humblet C, Lunney EA, Pavlovsky A, Rubin JR, Ferguson D, Graham N, Holler T, Hupe D, Nouhan C, Tummino PJ, Urumov A, Zeikus E, Zeikus G, Gracheck SJ, Erickson JW, et al.

Bioorg Med Chem. 1999 Dec;7(12):2775-800.

PMID:
10658583
49.

Helicobacter pylori physiology predicted from genomic comparison of two strains.

Doig P, de Jonge BL, Alm RA, Brown ED, Uria-Nickelsen M, Noonan B, Mills SD, Tummino P, Carmel G, Guild BC, Moir DT, Vovis GF, Trust TJ.

Microbiol Mol Biol Rev. 1999 Sep;63(3):675-707. Review.

50.

Nonpeptidic HIV protease inhibitors: 6-alkyl-5,6-dihydropyran-2-ones possessing a novel and achiral 3-(2-t-butyl-5-methyl-4-sulfamate)phenylthio moiety.

Vara Prasad JV, Markoski LJ, Boyer FE, Domagala JM, Ellsworth EL, Gajda C, Hagen SE, Tait BD, Lunney EA, Tummino PJ, Ferguson D, Holler T, Hupe D, Nouhan C, Gracheck SJ, VanderRoest S, Saunders J, Iyer K, Sinz M.

Bioorg Med Chem Lett. 1999 Aug 2;9(15):2217-22.

PMID:
10465549

Supplemental Content

Loading ...
Support Center